TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01491490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken once a day for 6 weeks
Study: NCT00042367
Drug: Induction therapy (Regimen 1, Course 1, Cycle A1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)
Study: NCT00042367
Drug: Regimen 1, Course 1, Cycle A2 (Days 22 - 42)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
Study: NCT03956446
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
Study: NCT03956446
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study: NCT04181762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00002970
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT00042367
Drug: Cycle B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC \< 500/mm3 or platelets (unsupported) \< 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1.
Study: NCT00042367
Drug: Regimen 1, Course 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
Study: NCT00042367
Drug: Regimen 2, Course 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is \< 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is \> 2000 on two consecutive days, post ANC nadir.
Study: NCT00042367
Drug: Regimen 2, Course, 1, Cycle C1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2.
Study: NCT00042367
Drug: Regimen 2, Course 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
Study: NCT03897881
Drug: mRNA-4157
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized Neoantigen Therapy
Study: NCT06385977
Drug: medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of medication
Study: NCT02776371
Drug: Modified non-clarithromycin triple therapy
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
Study: NCT02776371
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
Study: NCT02061800
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
Study: NCT02320318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
Study: NCT00560183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules
Study: NCT02378350
Drug: Peritoneal Dialysis treatment (no specific drug is defined)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02935101
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: formulated for oral administration. encapsulated.
Study: NCT02935101
Drug: Placebo (for Prednisolone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Prednisolon 10mg capsules
Study: NCT01213550
Drug: Placebo mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00417573
Drug: IV Gamunex 10%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04471597
Drug: normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml of normal saline 0.9% topically 15 min will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and the patient will be mechanically ventilated as usual.
Study: NCT01880099
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo compared to 8mg of Galantamine
Study: NCT03083132
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule oral daily
Study: NCT01473056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, twice a day or three times a day for 3 days
Study: NCT01936077
Drug: Recombinant LH (Luveris)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU recombinant LH daily.
Study: NCT00563303
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
Study: NCT01721070
Drug: Sufentanil NanoTab (SUF NT) 15 mcg
Normalized name: sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Period 1: One dose of SUF NT 15 mcg administered sublingually
Study: NCT01721070
Drug: Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
Study: NCT06478355
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy: intravenously, every 3 weeks for at least 6 months, or until progression, intolerance, or spontaneous withdrawal of the patient.
Study: NCT00687232
Drug: AZD4818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
Study: NCT00687232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03163784
Drug: Antibiotic Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets manufactured to mimic antibiotics
Study: NCT00092690
Drug: MK0653A, ezetimibe (+) simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01520454
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
Study: NCT01805271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (5 or 10 mg/day, i.e. 1 or 2 tablets/day)
Study: NCT02087423
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.
Study: NCT01122472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 3 weeks every 4 weeks for 24 months
Study: NCT00543738
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01522729
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours
Study: NCT01522729
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo \[NaCl\]
Study: NCT00218127
Drug: Levoacetyl Methadol
Normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
Study: NCT00218127
Drug: Levoacetyl Methadol
Normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
Study: NCT00218127
Drug: Levoacetyl Methadol
Normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM Fixed Dose evaluation up to 48 mg 48 mg
Study: NCT03813771
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
Study: NCT06202456
Drug: Huazhi Rougan granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huazhi Rougan granule
Study: NCT01464944
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
Study: NCT01464944
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
Study: NCT01464944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
Study: NCT00650234
Drug: Glucophage® XR Tablets 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg, single dose fasting
Study: NCT03011333
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 (bupivacaine/meloxicam) via nerve block or instillation.
Study: NCT03011333
Drug: Bupivacaine HCl without epinephrine
Normalized name: bupivacaine hydrochloride / epinephrine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine HCl without epinephrine, 50 mg via nerve block.
Study: NCT03011333
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo via nerve block.
Study: NCT02309918
Drug: LDV/SOF FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
Study: NCT06135675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration orally.
Study: NCT03131453
Drug: CNP520 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsule
Study: NCT03131453
Drug: CNP520 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg capsule
Study: NCT04024761
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CP), also known as cytophosphane among other names, is a chemotherapy agent
Study: NCT04096170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
Study: NCT02378623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
Study: NCT02497300
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02497300
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01213355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, single dose, oral, 1 day
Study: NCT01321112
Drug: conversion from CNI to MMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
Study: NCT04245371
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Patch
Study: NCT03673384
Drug: Xyzal Oral Product
Normalized name: Xyzal Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
Study: NCT01049399
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder for oral suspension administered once daily in fasting conditions for 52 weeks
Study: NCT02298504
Drug: Biodentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vital pulp therapy
Study: NCT02614703
Drug: Chromoendoscopy using Acetic Acid 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spraying esophageal mucosa during random biopsies for Barrett's esophagus
Study: NCT01265888
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
Study: NCT01265888
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
Study: NCT01265888
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
Study: NCT00003637
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03599752
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive chemotherapy
Study: NCT02270983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02351973
Drug: Hydrochlorthiazide
Normalized name: HYDROCHLORTHIAZIDE 25MG/VALSARTAN 160MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Study: NCT02670343
Drug: Oral Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
Study: NCT02351973
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Study: NCT02351973
Drug: Hydrochlorthiazide and Amiloride
Normalized name: amiloride / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 12.5 to 25mg \& + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many.
Study: NCT00361257
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline antibiotic, 100 mg taken orally every 12 hours
Study: NCT00361257
Drug: Placebo (Tetracycline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline antibiotic placebo, orally every 12 hours
Study: NCT01797419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral liquid, .5 mL/kg
Study: NCT03739853
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used in all three arms of study
Study: NCT01147458
Drug: PF-04191834 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching PF-04191834 placebo tablets to be administered BID for two weeks
Study: NCT02199860
Drug: SD I
Normalized name: Alphanine SD Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02199860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01147458
Drug: Naproxen placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching naproxen placebo tablets to be administered BID for 4 weeks
Study: NCT01585233
Drug: ASKP1240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT04082832
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension
Study: NCT01147458
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500 mg tablet administered BID for a total of four weeks